| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $88M | ||
| $82M |
Buys | $201,694 | 2 | 2 |
Sells | $212,362,752 | 98 | 98 |
| Desjardins Clarissa | director | 2 | $201,694 | 0 | $0 | $201,694 |
| MCGIRR DAVID W J | director | 0 | $0 | 2 | $451,535 | $-451,535 |
| ANDERSON ELIZABETH M | director | 0 | $0 | 2 | $2.98M | $-2.98M |
| Adsett Roger | Chief Operating Officer | 0 | $0 | 9 | $5.88M | $-5.88M |
| SHAROKY MELVIN MD | director | 0 | $0 | 4 | $8.06M | $-8.06M |
| LEE LEO | director | 0 | $0 | 1 | $14.69M | $-14.69M |
| Smith Michael Alexander | Chief Legal Officer | 0 | $0 | 14 | $15.56M | $-15.56M |
| Bonstein Sara | Chief Financial Officer | 0 | $0 | 11 | $24.31M | $-24.31M |
| Lewis William | Chair and CEO | 0 | $0 | 26 | $42.19M | $-42.19M |
| Schaeffer Orlov S Nicole | Chief People Strategy Officer | 0 | $0 | 9 | $46.71M | $-46.71M |
| Flammer Martina M.D. | Chief Medical Officer | 0 | $0 | 20 | $51.52M | $-51.52M |
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Over the last 12 months, insiders at Insmed Incorporated have bought $201,694 and sold $212.36M worth of Insmed Incorporated stock.
On average, over the past 5 years, insiders at Insmed Incorporated have bought $746,422 and sold $69.07M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Desjardins Clarissa (director) — $201,694.
The last purchase of 1,130 shares for transaction amount of $74,976 was made by Desjardins Clarissa (director) on 2025‑05‑21.
| 2026-03-05 | Sale | Lewis William | Chair and CEO | 10,699 0.005% | $146.03 | $1.56M | -1.62% | |
| 2026-02-24 | Sale | Smith Michael Alexander | Chief Legal Officer | 24,774 0.0114% | $155.77 | $3.86M | -7.56% | |
| 2026-02-19 | Sale | Lewis William | Chair and CEO | 10,699 0.005% | $150.97 | $1.62M | -4.06% | |
| 2026-02-09 | Sale | Lewis William | Chair and CEO | 13,396 0.0062% | $147.79 | $1.98M | -1.25% | |
| 2026-02-05 | Sale | Flammer Martina M.D. | Chief Medical Officer | 869 0.0004% | $152.44 | $132,470 | -3.97% | |
| 2026-02-03 | Sale | Lewis William | Chair and CEO | 3,009 0.0014% | $156.34 | $470,427 | -5.12% | |
| 2026-02-03 | Sale | Adsett Roger | Chief Operating Officer | 791 0.0004% | $156.17 | $123,530 | -5.12% | |
| 2026-02-03 | Sale | Flammer Martina M.D. | Chief Medical Officer | 795 0.0004% | $155.77 | $123,837 | -5.12% | |
| 2026-02-03 | Sale | Bonstein Sara | Chief Financial Officer | 748 0.0003% | $156.34 | $116,942 | -5.12% | |
| 2026-02-03 | Sale | Smith Michael Alexander | Chief Legal Officer | 640 0.0003% | $156.27 | $100,013 | -5.12% | |
| 2026-02-02 | Sale | Flammer Martina M.D. | Chief Medical Officer | 7,982 0.0038% | $154.59 | $1.23M | -3.36% | |
| 2026-01-20 | Sale | Lewis William | Chair and CEO | 10,699 0.0049% | $158.93 | $1.7M | -4.63% | |
| 2026-01-12 | Sale | Lewis William | Chair and CEO | 19,215 0.0091% | $169.00 | $3.25M | -8.69% | |
| 2026-01-09 | Sale | Flammer Martina M.D. | Chief Medical Officer | 1,887 0.0009% | $186.19 | $351,341 | -12.81% | |
| 2026-01-08 | Sale | Lewis William | Chair and CEO | 3,223 0.0015% | $174.17 | $561,350 | -9.68% | |
| 2026-01-08 | Sale | Adsett Roger | Chief Operating Officer | 2,059 0.001% | $174.17 | $358,616 | -9.68% | |
| 2026-01-08 | Sale | Flammer Martina M.D. | Chief Medical Officer | 4,911 0.0024% | $174.07 | $854,851 | -9.68% | |
| 2026-01-08 | Sale | Bonstein Sara | Chief Financial Officer | 1,447 0.0007% | $174.17 | $252,024 | -9.68% | |
| 2026-01-08 | Sale | Smith Michael Alexander | Chief Legal Officer | 1,053 0.0005% | $174.17 | $183,401 | -9.68% | |
| 2026-01-07 | Sale | Lewis William | Chair and CEO | 2,357 0.0011% | $175.07 | $412,640 | -12.42% |
| Lewis William | Chair and CEO | 301185 0.1397% | $42.02M | 7 | 62 | +45.59% |
| SHAROKY MELVIN MD | director | 243948 0.1132% | $34.03M | 13 | 11 | +30.83% |
| Adsett Roger | Chief Operating Officer | 106810 0.0496% | $14.9M | 1 | 33 | +43.16% |
| MCGIRR DAVID W J | director | 97723 0.0453% | $13.63M | 0 | 2 | |
| Flammer Martina M.D. | Chief Medical Officer | 83243 0.0386% | $11.61M | 0 | 48 | |
| Bonstein Sara | Chief Financial Officer | 79758 0.037% | $11.13M | 0 | 28 | |
| ANDERSON ELIZABETH M | director | 58729 0.0272% | $8.19M | 0 | 2 | |
| LEE LEO | director | 54677 0.0254% | $7.63M | 1 | 1 | +15.36% |
| Smith Michael Alexander | Chief Legal Officer | 51871 0.0241% | $7.24M | 0 | 35 | |
| Schaeffer Orlov S Nicole | Chief People Strategy Officer | 41754 0.0194% | $5.82M | 0 | 39 | |
| Desjardins Clarissa | director | 3025 0.0014% | $421,987.50 | 2 | 0 | |
| ALLAN GEOFFREY | President, CEO and Chairman | 1166464 0.5412% | $162.72M | 1 | 0 | +1.39% |
| ENGELSEN STEINAR J | director | 320802 0.1488% | $44.75M | 9 | 0 | +12.65% |
| TULLY KEVIN P | Executive VP & CFO | 142252 0.066% | $19.84M | 1 | 0 | <0.0001% |
| Pellizzari Christine A | Chief Legal Officer | 140721 0.0653% | $19.63M | 4 | 8 | |
| Wise John Drayton | Chief Commercial Officer | 133015 0.0617% | $18.56M | 0 | 17 | |
| Brennan David R | director | 80876 0.0375% | $11.28M | 1 | 0 | <0.0001% |
| Glover Steve C | President Follow-on Biologics | 80000 0.0371% | $11.16M | 1 | 0 | <0.0001% |
| Farrar Doug | Vice President, ITP | 74813 0.0347% | $10.44M | 4 | 0 | <0.0001% |
| HAYDEN DONALD J JR | director | 62197 0.0289% | $8.68M | 3 | 8 | <0.0001% |
| CROOKE GRAHAM K | director | 60000 0.0278% | $8.37M | 3 | 0 | <0.0001% |
| SORIANO JOHN | Chief Compliance Officer | 35204 0.0163% | $4.91M | 0 | 5 | |
| WHITCOMB RANDALL W | director | 29840 0.0138% | $4.16M | 2 | 1 | <0.0001% |
| ALTOMARI ALFRED | director | 20938 0.0097% | $2.92M | 0 | 5 | |
| Whitten Timothy | President & CEO | 10000 0.0046% | $1.4M | 2 | 0 | +43.09% |
| Drechsler Andrew T | Chief Financial Officer | 5000 0.0023% | $697,500.00 | 0 | 2 | |
| FMR LLC | 10 percent owner | 2221 0.001% | $309,829.50 | 0 | 21 | |
| GUPTA RENU | EVP & Chief Medical Officer | 2000 0.0009% | $279,000.00 | 2 | 0 | <0.0001% |
| POTTER MYRTLE S | director | 0 0% | $0 | 0 | 2 | |
| CONDON KENNETH G | director | 100 0% | $13,950.00 | 0 | 15 | |
| Quigley Mark | Vice President, Quality | 0 0% | $0 | 0 | 1 |
$961,890,236 | 276 | 22.46% | $18.42B | |
$211,610,344 | 91 | 38.45% | $10.1B | |
$2,765,836 | 72 | 20.00% | $11.25B | |
$2,449,191,716 | 58 | 16.50% | $77.49B | |
Insmed Incorporated (INSM) | $11,789,714 | 49 | 14.35% | $30.07B |
$323,530,732 | 48 | 29.90% | $41.57B | |
$88,307,390 | 38 | -1.70% | $10.99B | |
$19,233,721 | 36 | 70.14% | $11.06B | |
$13,655,378 | 35 | 17.13% | $23.5B | |
$15,836,193 | 25 | 17.98% | $119.21B | |
$415,090,639 | 19 | -14.04% | $13.46B | |
$143,065,458 | 17 | 8.01% | $18.8B | |
$1,279,017 | 16 | 51.12% | $7.98B | |
$152,272,932 | 16 | -10.78% | $19.56B | |
$627,701,115 | 15 | 145.68% | $12B | |
$284,820 | 10 | 45.67% | $11.76B | |
$55,713,031 | 8 | -0.36% | $8.63B | |
$40,276,273 | 4 | 34.57% | $20.08B | |
$999,989 | 1 | 262.16% | $20.76B |
| Increased Positions | 440 | +72.97% | 30M | +14.06% |
| Decreased Positions | 274 | -45.44% | 30M | -13.95% |
| New Positions | 194 | New | 6M | New |
| Sold Out Positions | 82 | Sold Out | 7M | Sold Out |
| Total Postitions | 769 | +27.53% | 214M | +0.11% |
| Jpmorgan Chase & Co | $4.08M | 10.82% | 23.05M | +7M | +47.4% | 2025-09-30 |
| Darwin Global Management, Ltd. | $3.62M | 9.6% | 20.46M | +1M | +5.75% | 2025-09-30 |
| Vanguard Group Inc | $3.53M | 9.36% | 19.94M | +2M | +12.99% | 2025-09-30 |
| Blackrock, Inc. | $2.19M | 5.81% | 12.36M | +1M | +10.97% | 2025-09-30 |
| Fmr Llc | $1.63M | 4.31% | 9.18M | +4M | +80.26% | 2025-09-30 |
| Capital International Investors | $1.34M | 3.55% | 7.55M | +74,994 | +1% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $1.23M | 3.25% | 6.93M | -4M | -38.28% | 2025-09-30 |
| Baker Bros. Advisors Lp | $1.19M | 3.15% | 6.7M | -1M | -13.09% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $1M | 2.66% | 5.66M | +2M | +65.3% | 2025-09-30 |
| Artisan Partners Limited Partnership | $874,562.00 | 2.32% | 4.94M | +2M | +48.98% | 2025-09-30 |